弥漫大B细胞淋巴瘤患者血浆MGMT基因甲基化与化疗疗效关系  

Relationship between methylation of MGMT gene in plasma of patients with diffuse large B-cell lymphoma and efficacy of chemotherapy

作　　者：康马飞[1] 骆梅青[1] 刘瑛[1] 廖漓漓[1] 陈莹[1] 

机构地区：[1]桂林医学院附属医院肿瘤内科,桂林541001

出　　处：《中国癌症防治杂志》2011年第3期210-213,共4页CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT

基　　金：广西卫生厅科研基金资助课题(Z2008271)

摘　　要：目的检测弥漫大B细胞淋巴瘤(DLBCL)患者外周血血浆中O6-甲基鸟嘌呤-DNA甲基转移酶(O6-methylgua-nine-DNA methyltransferase,MGMT)基因的甲基化状态,探讨MGMT基因甲基化与含烷化剂方案治疗DLBCL疗效的关系。方法利用巢式甲基化特异性聚合酶链反应法检测CHOP方案治疗前后DLBCL患者外周血血浆MGMT基因的甲基化状态。结果 30例DLBCL患者血浆MGMT基因甲基化率为63.3%(19/30),血浆MGMT基因甲基化者化疗有效率为100.0%(19/19),非甲基化者化疗有效率为72.7%(8/11),两组化疗有效率差异有统计学意义(P=0.041)。血浆MGMT基因甲基化者化疗后耐药发生率为10.5%(2/19),非甲基化者耐药发生率为54.5%(6/11),两组化疗耐药率差异有统计学意义(P=0.028)。结论外周血血浆中MGMT基因甲基化可能是预示DLBCL使用含烷化剂方案化疗疗效和耐药的指标。Objective To detect the methylation of gene O6-methylguanine DNA methyhransferase （MGMT） in peripheral plasma of patients with diffuse large B-cell lymphoma （DLBCL） ,and to evaluate the relationship between methylation of MGMT and efficacy of chemotherapy on DLBCL Methods Before and after chemotherapy, nested-methylation specific PCR （nMSP） was performed for detecting methylation of MGMT in plasma from DLBCL patients who were treated with CHOP. Results Methylation of MGMT was found in 63.3% （19/30） of patients with DLBCL The response rates were 100% （ 19/19 ） in patients with methylation of MGMT and 72. 7% （8/11 ） in patients with non-methylation of MGMT, and the difference between two groups was statistically significant （ P = 0. 041 ）. The ratios of resistance to chemotherapy were 10. 5% （ 2/19 ） in pa- tients with methylation of MGMT and 54. 5% （6/11） in patients with non-methylation of MGMT, and the difference between two groups was statistically significant （ P = 0. 028 ）. Conclusion Methylation of MGMT in peripheral plasma of DLBCL patients might be a biomarker of response or resistant to chemotherapy with alkylating agents based regimens.

关 键 词：淋巴瘤 弥漫大B细胞淋巴瘤 MGMT基因 DNA甲基化 化学疗法 

分 类 号：R733.4[医药卫生—肿瘤]